Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 8902 results

  1. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  4. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  5. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  6. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  7. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  8. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  11. Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]

    Awaiting development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    Awaiting development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development